Latest Phase II Data Bolster Cidara’s Antifungal
Executive Summary
Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.
You may also be interested in...
Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections
Phase III data for the novel echinocandin demonstrated non-inferiority to caspofungin for all-cause mortality at day 30 and for global cure at day 14. Regulatory filings are planned for 2022.
Cidara Aims For Treatment, Prophylaxis Claims For Novel Antifungal
Biotech says rezafungin should best existing echinocandin agents in treatment of Candida pathogen infections, while also offering needed prophylaxis improvements for leukemia and lymphoma patients.
Cidara, Janssen To Tackle Flu With Antiviral Conjugates
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.